glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Bexagliflozin was approved in the United States under the brand name Brenzavvy in January 2023. Canagliflozin is the first SGLT2 inhibitor to be approved for use in the United States. It was approved in March 2013, under the brand name Invokana, and it was also marketed throughout the European Union under the same name. Dapagliflozin (brand name Forxiga) was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. It was approved for use in the United States under the brand name Farxiga in January 2014. Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. Enavogliflozin, developed by GC Pharma and Daewoong Pharmaceutical. Approved for clinical use in South Korea and Ecuador. Ertugliflozin was approved in the United States under the brand name Steglatro in December 2017. Henagliflozin, selective SGLT2 inhibitor. Approved in China in 2022. Ipragliflozin, produced by the Japanese company Astellas Pharma Inc. under the brand name Suglat, approved in Japan in January 2014. Luseogliflozin, developed by Taisho Pharmaceutical, was approved in Japan in March 2014, under the brand name Lusefi. Remogliflozin etabonate was commercially launched first in India by Glenmark in May 2019.
=== History === The lineage of the 1st Transportation Detachment, 2nd Mobile Corps dates back to the 2nd World War, when it was known as the Laiyuan guerilla detachment of the Jin-Cha-Ji Military district. It participated in the Chinese civil war, WW2 and the Korean war. After becoming part of the PLA Basic Engineering Corps it was deployed to build the Duku Highway in 1974 in which 47 personnel lost their lives. Prior to 1984, the transportation corps was part of the People's Liberation Army Basic Engineering Corps. The 7th Transportation Detachment assisted in disaster relief after the 2015 Tianjin explosions. The 6th Detachment of the transportation corps deployed 105 officers and 48 vehicles for urban search and rescue duties during the 2015 Shenzhen landslide.
== External links == Academy of Managed Care Pharmacy American College of Clinical Pharmacy Board of Pharmacy Specialties Journal of Clinical Pharmacy and Therapeutics The British Journal of Clinical Pharmacy United Kingdom Clinical Pharmacy Association Clinical Pharmacy Education, Practice and Research
== List of SERT-selective SRIs == Many SRIs exist, an assortment of which are listed below. Note that only SRIs selective for the SERT over the other monoamine transporters (MATs) are listed below. For a list of SRIs that act at multiple MATs, see other monoamine reuptake inhibitor pages such as SNRI and SNDRI.
Over the November 2016 Thanksgiving holiday weekend, President-Elect Donald Trump tweeted that he was in talks with Carrier Management to keep the factory in Indiana and not move to Mexico. On November 30, 2016, Carrier announced that it had negotiated an agreement with President-elect Trump and Vice President-elect Mike Pence to continue manufacturing gas furnaces in Indianapolis, in addition to retaining engineering and headquarters staff, preserving more than 1,000 jobs in Indianapolis. The agreement included a state incentive package of about $7 million over 10 years. The number of jobs saved was later revised down to 800. In May 2017, as part of their previously announced plan, Carrier told the state of Indiana that it will cut 632 jobs from its Indianapolis factory. Layoffs began at the end of July 2017, with each worker receiving one week's salary for each year of employment, education and job training, plus 6 months of health insurance as part of the severance package. The New York Times reported on August 10, 2018, that Carrier's Indianapolis furnace plant was plagued by low morale and absenteeism because "employees share a looming sense that a factory shutdown is inevitable — that Carrier has merely postponed the closing until a more politically opportune moment." On November 26, 2018, United Technologies announced that it would spin off UTC Climate, Controls & Security as an independent company known as Carrier Global Corporation. In April 2020, United Technologies announced that the separation and spin-off of Carrier had been completed.
Sources: en.wikipedia.org
Sanctioned Parts List – a habitation / factory ship So Much For Subtlety – a habitation / factory ship All Through With This Niceness And Negotiation Stuff – a warship Attitude Adjuster – a warship Of Course I Still Love You – an ambassador ship Funny, It Worked Last Time... – an ambassador ship
Improper management of health care waste can have both direct and indirect health consequences for health personnel, community members and on the environment. Indirect consequences in the form of toxic emissions from inadequate burning of medical waste, or the production of millions of used syringes in a period of three to four weeks from an insufficiently well planned mass immunization campaign. Biomedical waste is not limited to medical instruments; it includes medicine, waste stored in red biohazard bags, and materials used for patient care, such as cotton and bandaids. The most serious effect that biomedical waste has on our seas is the discharge of poisons into the waters that could then be consumed by ocean life creatures. Toxins would interject into the food chain and eventually reach humans who consume sea creatures. Human exposure to such toxins can stunt human growth development and cause birth defects. The high volume of plastic use in the medical field also poses a dangerous threat to the environment. According to North and Halden, 85% of disposable plastic materials make up all medical equipment. Our current reliance on plastic materials is rooted in their unique capabilities to be lightweight, cost-effective, and durable while preserving the sterility of medical equipment. In addition to the serious health implications of releasing harmful toxins in the environment from medical waste deposits, introducing this volume of single-use plastics can catalyze the compounding health detriments caused by macro and microplastics.
One important property of carbon is that it readily forms chains, or networks, that are linked by carbon-carbon (carbon-to-carbon) bonds. The linking process is called polymerization, while the chains, or networks, are called polymers. The source compound is called a monomer. Two main groups of polymers exist: synthetic polymers and biopolymers. Synthetic polymers are artificially manufactured, and are commonly referred to as industrial polymers. Biopolymers occur within a respectfully natural environment, or without human intervention.
Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin, a succinate salt, is chemical compound which is claimed by its manufacturer, the Russian company Pharmasoft Pharmaceuticals, to have antioxidant and actoprotector properties, but these purported properties of emoxypine have not been proven. Its chemical structure resembles that of pyridoxine (a type of vitamin B6).
Sources: en.wikipedia.org
S8 + 8 O2 → 8 SO2, ΔH = −297 kJ/mol To aid combustion, liquified sulfur (140–150 °C (284–302 °F) is sprayed through an atomizing nozzle to generate fine drops of sulfur with a large surface area. The reaction is exothermic, and the combustion produces temperatures of 1,000–1,600 °C (1,830–2,910 °F). The significant amount of heat produced is recovered by steam generation that can subsequently be converted to electricity. The combustion of hydrogen sulfide and organosulfur compounds proceeds similarly. For example:
According to Analayo, each of the twelve nidanas "re-quires all five aggregates to be in existence concurrently." Furthermore:The teaching on dependent arising does not posit the existence of any of the links in the abstract, but instead show how a particular link, as an aspect of the continuity of the five aggregates, has a conditioning influence on another link. It does not imply that any of these links exist apart from the five aggregates.
=== Psychological === Common psychological side effects from clonidine include sedation, drowsiness, and dizziness. The sedative effect of intravenous clonidine is dose-dependent and attributed in part to α2B adrenoceptor activation in the thalamus. Sleep disturbance and depressed mood have been reported, and the Australian Medicines Handbook advises caution in people with a history of depression. Less common neuropsychiatric reactions reported with clonidine (i.e., <1%) include disturbed mental state, nightmares, confusion, hallucinations, and delusions.
Elevated SIRs (which is risk of getting cancer) were found for subgroups in the USA cohort defined by age <35 years or childhood onset GH deficiency." The FDA issued a Safety Communication in August 2011, stating that the evidence regarding recombinant human growth hormone and increased risk of death is inconclusive after reviewing sources including a French study which compared persons with certain kinds of short stature (idiopathic growth hormone deficiency and idiopathic or gestational short stature) treated with recombinant human growth hormone during childhood and who were followed over a long period of time, with individuals in the general population of France.
The Meiji government assured the foreign powers that it would follow the old treaties negotiated by the bakufu and announced that it would act in accordance with international law. Mutsuhito, who was to reign until 1912, selected a new reign name—Meiji, or "Enlightened Rule"—to mark the beginning of a new era in Japanese history. To further dramatize the new order, the capital was relocated from Kyoto, where it had been situated since 794, to Tokyo (Eastern Capital), the new name for Edo. In a move critical for the consolidation of the new regime, most daimyōs (feudal lords) voluntarily surrendered their land and census records to the Emperor in the abolition of the Han system, symbolizing that the land and people were under the Emperor's jurisdiction. Confirmed in their hereditary positions, the daimyo became governors, and the central government assumed their administrative expenses and paid samurai stipends. The han were replaced with prefectures in 1871, and authority continued to flow to the national government. Officials from the favored former han, such as Satsuma, Chōshū, Tosa, and Hizen staffed the new ministries. Formerly old court nobles, and lower-ranking samurai, replaced bakufu appointees and daimyo as a new ruling class appeared.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Dry powder is kept frozen, commonly at minus twenty degrees Celsius or below. It should be protected from light and moisture. Dissolved material is less stable and is generally used soon after preparation.